How could the FDA's handling of biologics applications affect the Center for Biologics Evaluation and Research?
FDA's handling of biologics applications may shift CBER's operational focus The FDA's decisions regarding biologics applications, such as the ongoing review of Savara's molgramostim or the rejection issued to Capricor, directly influence the operational demands placed on the Center for Biologics Evaluation and Research (CBER). CBER is the specialized division responsible for evaluating these complex submissions. The mix of ongoing reviews, missed goal dates, and complete response letters requires CBER to manage fluctuating workloads and allocate resources across diverse and challenging scientific cases.
- Effect
- Mixed
- How direct
- Stated in the reporting
- When
- Over the long term
- The story
- Still developing
How it reaches Center for Biologics Evaluation and Research
-
The FDA confirmed that the review of Savara Inc.'s inhaled drug, molgramostim, will not meet its goal date of November 22, 2026, and no new date has been set. The agency stated the review remains ongoing and did not issue a formal rejection letter. Separately, the FDA issued a rejection to Capricor Therapeutics for its cell therapy, deramiocel.
The full event1independent outlet -
The FDA is currently reviewing Savara's molgramostim, an inhaled drug for autoimmune pulmonary alveolar proteinosis, which is a biologics license application. Separately, the agency issued a complete response letter and a rejection to Capricor. As the specialized research center under the FDA, CBER is responsible for evaluating these complex biologics submissions. The ongoing reviews and rejections directly influence the division's operational workload and resource allocation.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- techtimes.com 10 hours ago
-
FDA research center
Everything about Center for Biologics Evaluation and Research
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Savara's molgramostim is an inhaled drug for autoimmune pulmonary alveolar proteinosis (aPAP) and is a biologics license application.techtimes.com
- The FDA issued a complete response letter and a rejection to Capricor Therapeutics.techtimes.com
- The FDA's hiring data showed headcount at the Center for Drug Evaluation and Research fell from 6,044 at the start of fiscal 2025 to 4,961 through Sept. 30, 2026, about an 18% drop.techtimes.com
Why it matters
The Center for Biologics Evaluation and Research is tasked with maintaining the integrity of the drug approval process for complex biological therapies. The volume and nature of applications—ranging from ongoing reviews like molgramostim to outright rejections like Capricor's—determine the division's operational tempo and the resources needed to ensure rigorous scientific evaluation.
This workload is set against a backdrop of documented staffing changes within the FDA. While the reports do not tie the staffing drop directly to the current delays, the overall bandwidth of the agency impacts its ability to manage the growing complexity of biologics submissions, which are critical for treating rare diseases like aPAP.
What we don't know yet
- Will the FDA adjust its staffing or resource allocation to manage the current volume of complex biologics reviews?
- Will the ongoing review of molgramostim lead to a new, firm goal date for the application?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- European Medicines AgencyPossibleSavara's US drug review delay may influence EMA's European decision
- companyPossibleRegulatory uncertainty in rare disease drug development may increase risk for companies.
- United States of AmericaPossibleIncreased uncertainty over aPAP treatments could prolong reliance on invasive care in the US
Reporting
- techtimes.com10 hours ago
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.